Recombinant human mannan-binding lectin
US6846649B1 · kind B1 · utility
32Cited by
2References
30Claims
0Family size
Inventors
Key dates
| Filing date | May 10, 2000 |
| Grant date | Jan 25, 2005 |
| Priority date | — |
| Expiry date | May 10, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/4726
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of producing and/or isolating MBL compositions. In particular the invention relates to methods of producing and/or isolating novel recombinant human MBL preparations with high similarity to natural human MBL. The MBL preparations may be used in compositions, medicaments and in methods for treatment of conditions such as those related to immunosuppressive conditions and/or to conditions of MBL deficiencies including latent conditions. Conditions of deficiencies of Mannan-Binding Lectin (MBL) are associated with increased susceptibility to infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.